Henri Parson
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Purpose We evaluated healthcare providers’ current knowledge, practices, and perspectives on a novel clinical decision tool (beta-version) to facilitate individualized exercise prescriptions and discussions in clinical settings. Methods We recruited healthcare providers who had treated or provided care to breast cancer survivors aged ≥ 35-years in the past 12 months. The participants were presented with a tool to provide individualized exercise recommendations considering women’s individual, clinical, and contextual characteristics. Validated and reliable pre-existing instruments were used to survey providers’ current knowledge, practices regarding exercise discussions, and perspectives on the beta-version (paper-draft) of the novel tool. Results The sample consisted of complete survey responses from 177 healthcare providers including breast oncologists (27.7%), primary care physicians (10.7%), exercise specialists (19.8%), occupational/physical therapists (18.1%), advanced care providers, nurses, navigators, and social workers (23.7%). Median years of experience was 8-years (range: 5–13). Overall, 62.1% ( n = 110) reported that they were knowledgeable about counseling survivors based on exercise guidelines. Among breast oncologists and primary care physicians ( n = 68), only 39.7% reported that they were knowledgeable about identifying patients for exercise referals. The majority agreed that they would find the tool offering individualized information useful ( n = 148, 83.6%), and would use it regularly to inform practice (82.5%). ‘Exercise Readiness’, ‘Exercise Resources at Home’, and ‘Quality-of-Life’ were the highest rated items for inclusion in the tool for exercise prescriptions. Provider perspectives were incorporated into the beta-version of the tool. Conclusion A clinical decision tool considering individual, clinical, and contextual characteristics may support exercise prescriptions and discussions in clinical settings. Implications for cancer survivors An evidence-based tool for exercise prescriptions may increase healthcare provider confidence to discuss, educate, encourage, and provide exercise referrals for breast cancer survivors.
Year:
2025
Introduction and Objective: Physical activity (PA) is a well-known intervention resulting in weight loss, improved physical fitness and metabolic parameters, thereby contributing to reduced risk of conditions such as type 2 diabetes, cardiovascular disease, hypertension, and hyperlipidemia. Interventions promoting healthy lifestyle are more likely to succeed if they are culturally tailored. The goal of this study is to assess the impact of a 48 week tiered, supervised, and culturally tailored PA intervention in obese AA women. Methods: This is a pilot, single arm study in obese AA females at risk for diabetes. The 48 week tiered exercise intervention included both in-person and virtual exercise sessions occurring 3 times/week with independent sessions starting at week 24. Outcome measures were assessed at baseline, 24- and 48 weeks. The supervised intervention included cardiovascular, resistance, balance, and flexibility exercises. Results: A total of 60 sedentary, obese AA females were enrolled in the study (mean age 51, weight 219 lbs, BMI 37, 31% hypertensive, 18% dyslipidemic, and 34% pre-diabetic. A total of 32 and 28 participants completed 24- and 48 weeks of exercise, respectively. Compared to baseline, significant improvements were seen as follows: 1) weight, body mass index, waist and hip circumference, and blood pressure at week 48; 2) functional mobility (timed up & go, 6-minute walk distance tests, and length walked) in both weeks 24 and 48; 3) total body fat (including arms, legs, trunk, and waist), percentage of lean tissue, and Norfolk Quality of Life-Fatigue Survey scores in both weeks 24 and 48; 4) HemoglobinA1c at week 24. There were no changes in fasting blood glucose, insulin, triglycerides, and cholesterol. Conclusion: These results indicate that a culturally sensitive, supervised exercise intervention for obese AA women can lead to sustained weight loss, increased functional mobility, reduced levels of fatigue and improvements in body composition as well as metabolic parameters. Disclosure H. Parson: None. K.S. Thomas: None. D. Wolf: None. C.M. Casellini: Employee; Eli Lilly and Company. J. Patel: None. T. Sears: None. M. Karpov: None. E.S. Siraj: Consultant; Novo Nordisk. Research Support; Novo Nordisk. Consultant; Boehringer-Ingelheim. Research Support; Boehringer-Ingelheim. Funding Eastern Virginia Medical School
Year:
2025
Year:
2025
Year:
2024
Mobile health (mHealth) lifestyle interventions for obesity have gained popularity. However, acceptance and efficacy of these in minority populations is less known. The aim of this study was to assess efficacy of a 12-week culturally sensitive mHealth dietary intervention on weight in African Americans (AA) Randomized 12-week pilot study of 43 overweight or obese AA. Subjects were randomized to mHealth intervention (INT) or Standard of Care (SOC). INT included virtual session with dietitian, customized meal plans based on personal preferences, and educational videos. SOC included CDC-guidelines on weight loss. Mixed Methods Repeated Measures analysis was used Baseline characteristics were similar between the groups (age 60 years, weight 204 lbs, 84% females, 67% hypertension, 56% dyslipidemia and 25% diabetes). Mean weight loss was 4.4 lbs for INT & 3.2 lbs for SOC. Weight significantly improved in both groups over time (p=0.0002) but there was no significant difference between the groups. 74% of INT and 68% of SOC lost weight (Figure 1) This study shows potential benefit of tailoring mHealth interventions in a minority population. Results should be interpreted within the context of small sample size and short duration. Qualitative feedback from participants led to improvements in INT and a larger and longer 48-weeks study is underway to better assess the efficacy of INT Disclosure C.M. Casellini: None. H. Parson: None. J.L. Pettaway: None. A.B. Austin-Stephens: None. E. Stephens: None. M.M. Bartholmae: None. A.M. Ingram: None. T. Sears: None. F. Haque: None. L. Ekdahl: None. F. Ayesha: None. E.S. Siraj: Consultant; Novo Nordisk. Research Support; Novo Nordisk. Consultant; Boehringer-Ingelheim, Eli Lilly and Company. Funding Hampton Roads Biomedical Research Consortium (HRBRC)
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (3)
Rachelle Brick
University of Pittsburgh
Jinani Jayasekera
Principle Investigator
University of Michigan
Takeo Fujii
Assistant Clinical Investigator
National Cancer Institute
Make your next move.
Prepare your application
Review drafts before you send them.